Drugging PI3K in cancer: refining targets and therapeutic strategies
about
Redox Control of Multidrug Resistance and Its Possible Modulation by AntioxidantsDiscovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)The therapeutic potential of targeting the PI3K pathway in pediatric brain tumorsFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceInhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsPI3K-resistant GSK3 controls adiponectin formation and protects from metabolic syndromePIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal modelsHER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.Increased expression of the PI3K catalytic subunit p110δ underlies elevated S6 phosphorylation and protein synthesis in an individual with autism from a multiplex family.Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDXThe Hidden Conundrum of Phosphoinositide Signaling in CancerEnhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.Targeting a novel cancer-driving protein (LAPTM4B-35) by a small molecule (ETS) to inhibit cancer growth and metastasis.Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis.Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells.CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.Towards pharmacological intervention in inositol pyrophosphate signalling.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Gastric cancer management: Kinases as a target therapy.Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancerNovel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.AKT Inhibition in Solid Tumors With AKT1 Mutations.Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.Investigating the effect of arachidonate supplementation on the phosphoinositide content of MCF10a breast epithelial cells.Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.Probing the PI3K/Akt/mTor pathway using (31)P-NMR spectroscopy: routes to glycogen synthase kinase 3.In Silico Study and Bioprospection of the Antibacterial and Antioxidant Effects of Flavone and Its Hydroxylated Derivatives.Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis.Phytochemicals and PI3K Inhibitors in Cancer—An Insight.Phytochemicals and PI3K Inhibitors in Cancer-An Insight.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.PI3K inhibition to overcome endocrine resistance in breast cancer.
P2860
Q26765805-0E35CDF3-3DBF-4173-86FD-778347D01A3CQ27711042-2071AA57-0619-4C1C-BC3E-8B4814E5F90FQ28070264-D2AFD9D7-3CEE-44EA-963E-4825E9FEFD3FQ28077347-73DE6487-73D6-435D-9562-DB174635E789Q28817295-AA627907-CFCE-4AF7-ADC6-608C7B7E33F1Q30315106-EF524AFC-EC2B-4A89-8E49-E8DCBAF3568DQ30805305-EA42A247-DE29-44B7-B56F-72F800E55046Q33626569-D63B0D32-48BD-4FDF-AD10-146A59232090Q33906319-6A525D40-5F03-4121-A027-B0B33436561CQ35919716-BF65C61B-DECC-4364-AF6A-613FECC3B7B5Q36461481-2A748469-B2CE-4F89-9AF6-04539E4265F0Q36806807-FD1314F3-4A5C-4387-9489-6B3636B232A2Q37346174-27334C1C-96AD-4916-A841-3EDECF43E1C4Q37391319-ED385745-E372-4406-8B0C-4E5744B394B7Q37421296-0D939121-1B0B-4353-AD25-BE478D9951F7Q37629059-95AE5B7B-05DB-463A-8559-2D78EBB79E1EQ37708928-975A034A-7C85-498C-A5DC-6B0B60519C0FQ37739700-6379D5D0-D240-487C-90FA-4313B992A3EBQ38672092-F0A92362-FB17-444C-BFD3-F17CFEEB05CBQ38684394-165BBBE4-2DCF-45CD-9EAF-64ED62D80DFCQ38702479-CAB07077-9E43-45F2-9E71-1F013A14ED74Q38723290-7A853296-FFBC-4601-9E7C-2875CD09A603Q38728101-FCA07F10-54C4-44A5-9F79-34FA5468F2EFQ38734451-8F4C2390-16D5-4D73-B416-91D799AD9C4BQ38749038-9CB40D1B-C1FA-4D5D-AF66-3C6CCCB4FA1FQ38751569-B4D2AE73-0B00-4076-A895-887BC2D0F2AFQ38785807-DE5F807F-7143-4665-B47A-78DFF3E0FF99Q38794254-1C867930-A9DF-4247-B838-E76E5ABFFF1AQ39036639-AB74DB1B-F0EE-4DAA-990B-20B34CB34614Q39229171-C596E984-1D1B-4FE2-9170-24ED8477AD2CQ40401733-A3EF3F12-588E-4A6C-8DE8-81E060CCC946Q41441736-517D4DCB-4FAE-4913-8AC6-92F4B75B30FDQ41471269-DC0161EB-789C-40CB-AC0C-4046CF47ED11Q42120404-16612D87-9922-4F17-AB77-6865DCF0EB42Q46361570-FA637E13-E940-4EEA-9E40-58286211A1B2Q47143132-47E69B0D-B510-41C4-84CF-3FF926B6D272Q47174924-0FFF7424-8C83-44B6-BEE5-CB87D9F370C2Q47222096-1E7D4F5E-17D3-43F3-B1E9-B745A6ECA7F3Q47393972-A59B004C-5F3D-4DE2-88A0-F4A97729C74CQ47776273-CDA1B456-1736-4074-A827-3ED29F4D7328
P2860
Drugging PI3K in cancer: refining targets and therapeutic strategies
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Drugging PI3K in cancer: refining targets and therapeutic strategies
@en
type
label
Drugging PI3K in cancer: refining targets and therapeutic strategies
@en
prefLabel
Drugging PI3K in cancer: refining targets and therapeutic strategies
@en
P2860
P921
P1476
Drugging PI3K in cancer: refining targets and therapeutic strategies
@en
P2093
Lynn Bjerke
Timothy A Yap
P2860
P304
P356
10.1016/J.COPH.2015.05.016
P5008
P577
2015-06-25T00:00:00Z
2015-08-01T00:00:00Z